Clinical and Molecular Hepatology

"Tae Hun Kim"

Review

Liver fibrosis, cirrhosis, and portal hypertension

Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis: Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim; Clin Mol Hepatol 2021;27(4):535-552.
Published online June 16, 2021; DOI: https://doi.org/10.3350/cmh.2021.0109

Abstract
PDF

Although patients with cirrhosis are known to be in a state of “rebalance” in that pro- and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT.

Citations

Citations to this article as recorded by

A glycoprotein UGP2A from the medicinal insect Ulomoides dermestoides alleviates deep vein thrombosis via the TLR4/MyD88 signaling pathway
Qun Yu, Caiyi Wang, Yadan Dong, Mingrong Li, Ting Yan, Heng Liu, Chenggui Zhang, Jiapeng Wang, Huai Xiao
International Journal of Biological Macromolecules.2026; 341: 150216. CrossRef
Sequential anticoagulation with LMWH and DOACs in cirrhotic portal vein thrombosis
Melis Onay, Myriam Heilani, Chaarvee Gulia, Christoph Matthias, Eva Herrmann, Vitali Koch, Leon David Grünewald, Albrecht Piiper, Stefan Zeuzem, Mate Knabe
Clinics and Research in Hepatology and Gastroenterology.2026; 50(4): 102792. CrossRef
Analysis of 6-week mortality and influencing factors in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding
Junli Zhang, Ling Feng, Chih-Wei Tseng
PLOS One.2026; 21(3): e0345079. CrossRef
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival
Madhumita Premkumar, Harish Bhujade, Prerna Sharma, Jasvinder Nain, Jasmina Ahluwalia, Anchal Sandhu, Yogendra Kumar, Sahaj Rathi, Sunil Taneja, Ajay Kumar Duseja, Anand V. Kulkarni, Charanpreet Singh, Shano Naseem, Tanka Karki, Pankaj Gupta, Sreedhara B.
Alimentary Pharmacology & Therapeutics.2025; 61(6): 971. CrossRef
Comprehensive approach to liver cirrhosis treatment: Integrating ayurveda, homeopathy, and allopathy
Debabrata Dash, Palak Kesharwani, Raj Kumar Koiri
Pharmacological Research - Natural Products.2025; 6: 100184. CrossRef
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis
Seema Sharma, Nishant Tiwari, Sampat Singh Tanwar
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(9): 11541. CrossRef
Machine learning models predict coagulopathy in traumatic brain injury patients in ER
Haoyu Wang, Wenying Cao, Jianhuang Huang, Yuxing Feng, Cheng Li
Frontiers in Neurology.2025;[Epub] CrossRef
Effect of Direct Oral Anticoagulants Versus Traditional Anticoagulation in Budd-Chiari Syndrome
Xiaojuan Wu, Lijuan Liang, Jinghong Liu
Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
The relationship between gastroduodenal lesions and coronary heart disease
N. U. Chamsutdinov, Ja. N. Abdulmanapova, N. A. Alieva, K. L. Seydalieva, A. R. Arbukhanova, M. A. Alakhverdieva, Z. M. Magomedova, R. G. Biybolatova
Meditsinskiy sovet = Medical Council.2025; (15): 58. CrossRef
Comparative Effectiveness and Safety of Various Anticoagulation Regimens for Portal Venous Thrombosis in Cirrhosis: A Systematic Review and Network Meta-Analysis
Zain ul Abideen, Muhammad Hassan Waseem, Noor Ul Huda Ramzan, Hamna Raheel, Fariha Hasan, Pawan Kumar Thada, Prasun K. Jalal
Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
Analysis of Related Influencing Factors of Portal Vein Thrombosis After Hepatectomy
ShiGuai Qi, Jie Tao, Xinhua Wu, Xu Feng, Guoying Feng, Zhengrong Shi
Journal of Laparoendoscopic & Advanced Surgical Techniques.2024; 34(3): 246. CrossRef
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis
Chunwei Cheng, Juan Hua, Liang Xiong
Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review
Xiulin Xiao, Wengen Zhu, Qixin Dai
Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article
Gareema Tyagi, Roshan K Jha
Cureus.2023;[Epub] CrossRef
THE SURGEON'S PERSPECTIVE ON PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS
S.M. Vasyliuk, V.I. Hudyvok, І.R. Labiak, N.M. Pavliuk, V.M. Atamaniuk
Art of Medicine.2023; : 152. CrossRef
Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances
Zhe Li, Wen-Tao Xu, Xiang-Bo Xu, Xing-Shun Qi
World Chinese Journal of Digestology.2022; 30(9): 381. CrossRef
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?
Xiaobing Wang, Liping Chen
Hepatology International.2022; 16(5): 1248. CrossRef
Direct oral anticoagulants (DOACs): From the laboratory point of view
Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum
Acta Pharmaceutica.2022; 72(4): 459. CrossRef

21,157 View
729 Download
16 Web of Science
Crossref

Original Article

Viral hepatitis

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B: Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh; Clin Mol Hepatol 2017;23(4):331-339.
Published online September 26, 2017; DOI: https://doi.org/10.3350/cmh.2016.0040

Abstract
PDF

Background/Aims
Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir (ETV) and lamivudine (LAM) over 240 weeks.
Methods
Treatment-naive patients with HBeAg-negative CHB were randomized to receive ETV 0.5 mg/day or LAM 100 mg/day during the 96 week double-blind phase, followed by open-label treatment through week 240. The primary endpoint was the proportion of patients with virologic response (VR; hepatitis B virus [HBV] DNA<300 copies/mL) at week 24. Secondary objectives included alanine aminotransferase (ALT) normalization and emergence of ETV resistance (week 96), VR and log reduction in HBV DNA levels (week 240), and safety evaluation.
Results
In total, 120 patients (>16 years old) were included (ETV, n=56; LAM, n=64). Baseline characteristics were comparable between the two groups. A significantly higher proportion of ETV-treated patients achieved VR compared to LAM at week 24 (92.9% vs. 67.2%, P=0.0006), week 96 (94.6% vs. 48.4%, P<0.0001), and week 240 (95.0% vs. 47.6%, P<0.0001). At week 96, ALT normalization was observed in 87.5% and 51.6% of ETV and LAM patients, respectively (P<0.0001). Virologic breakthrough occurred in one patient (1.8%) receiving ETV and 26 patients (42.6%) receiving LAM (P<0.0001) up to week 96. Emergence of resistance to ETV was not detected. The incidence of serious adverse events was low and unrelated to the study medications.
Conclusions
Long-term ETV treatment was superior to LAM, with a significantly higher proportion of patients achieving VR. Both treatments were well tolerated.

Citations

Citations to this article as recorded by

Viral oncogenesis in cancer: from mechanisms to therapeutics
Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
Emmanouil Sinakos, Nandita Kachru, Christos Tsoulas, Sushanth Jeyakumar, Nathaniel J Smith, Alon Yehoshua, Evangelos Cholongitas
Journal of Comparative Effectiveness Research.2024;[Epub] CrossRef
Entecavir: A Review and Considerations for Its Application in Oncology
Tânia Lourenço, Nuno Vale
Pharmaceuticals.2023; 16(11): 1603. CrossRef
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir
Hyunwoo Oh, Eileen L. Yoon, Dae Won Jun, Sang Bong Ahn, Hyo-Young Lee, Jae Yoon Jeong, Hyoung Su Kim, Soung Won Jeong, Sung Eun Kim, Jae-Jun Shim, Joo Hyun Sohn, Yong Kyun Cho
Clinical Gastroenterology and Hepatology.2020; 18(12): 2793. CrossRef
Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho, Suzane Kioko Ono
Journal of Gastroenterology.2020; 55(5): 496. CrossRef
Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma
Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn, Seung Up Kim
Journal of Viral Hepatitis.2020; 27(9): 932. CrossRef
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park
Clinical and Molecular Hepatology.2020; 26(3): 364. CrossRef
A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients
Urbano Sbarigia, Talitha Vincken, Peter Wigfield, Mahmoud Hashim, Bart Heeg, Maarten Postma
Journal of Comparative Effectiveness Research.2020; 9(15): 1051. CrossRef
Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults
Roger Chou, Ian Blazina, Christina Bougatsos, Rebecca Holmes, Shelley Selph, Sara Grusing, Janice Jou
JAMA.2020; 324(23): 2423. CrossRef
External validation of the modified PAGE‐B score in Asian chronic hepatitis B patients receiving antiviral therapy
Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Beom Kyung Kim
Liver International.2019; 39(9): 1624. CrossRef
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials
William W. L. Wong, Petros Pechivanoglou, Josephine Wong, Joanna M. Bielecki, Alex Haines, Aysegul Erman, Yasmin Saeed, Arcturus Phoon, Mina Tadrous, Mona Younis, Noha Z. Rayad, Valeria Rac, Harry L. A. Janssen, Murray D. Krahn
Systematic Reviews.2019;[Epub] CrossRef

12,838 View
236 Download
15 Web of Science
Crossref

Case Report

Infectious liver disease

A case of obstructive jaundice caused by tuberculous lymphadenitis: A literature review: Su Jung Baik, Kwon Yoo, Tae Hun Kim, Il Hwan Moon, Min-Sun Cho; Clin Mol Hepatol 2014;20(2):208-213.
Published online June 30, 2014; DOI: https://doi.org/10.3350/cmh.2014.20.2.208

Abstract
PDF

Obstructive jaundice caused by tuberculous lymphadenitis is a rare manifestation of tuberculosis (TB), with 15 cases having been reported in Korea. We experienced a case of obstructive jaundice caused by pericholedochal tuberculous lymphadenitis in a 30-year-old man. The patient's initial serum total bilirubin level was 21.1 mg/dL. Abdominal computed tomography revealed narrowing of the bile duct by a conglomerated soft-tissue mass involving the main portal vein. Abrupt obstruction of the common bile duct was observed on cholangiography. Pathologic analysis of a ultrasonography-guided biopsy sample revealed chronic granulomatous inflammation, and an endoscopic examination revealed esophageal varices and active duodenal ulceration, the pathology of which was chronic noncaseating granulomatous inflammation. Hepaticojejunostomy was performed and pathologic analysis of the conglomerated soft-tissue mass revealed chronic granulomatous inflammation with caseation of the lymph nodes. Tuberculous lymphadenitis should be considered in patients presenting with obstructive jaundice in an endemic area.

Citations

Citations to this article as recorded by

Obstructive jaundice caused by an abdominal tuberculous mass lesion
Wilson Jing Peng Liu, Michael Yulong Wu, Matthew Zaborowski, Eugene Ng
Clinical Journal of Gastroenterology.2025; 18(1): 202. CrossRef
Obstructive jaundice caused by tuberculous lymphadenitis accompanied by a mass in the pancreas: a case report
Jong In Jeon, Jung Wook Lee
Kosin Medical Journal.2025; 40(1): 66. CrossRef
Tuberculosis of Cystic Duct Lymph Node Associated with Cholecystitis
Tae Gil Heo, Seong Woo Hong, Yeo Goo Chang, Woo Yong Lee, Haeng Jin Ohe, Kyeong Woon Choi, Yun Kyung Kang
The Korean Journal of Gastroenterology.2021; 78(4): 245. CrossRef
Tuberculosis (TB) of the Porta Hepatis Presenting with Obstructive Jaundice Mimicking a Malignant Biliary Tumor: A Case Report and Review of the Literature
Rashid AL Umairi, Ahmed AL Abri, Atheel Kamona
Case Reports in Radiology.2018; 2018: 1. CrossRef
An HIV-positive Case of Obstructive Jaundice Caused by Immune Reconstitution Inflammatory Syndrome of Tuberculous Lymphadenitis Successfully Treated with Corticosteroids
Naoaki Watanabe, Ryota Sato, Hideaki Nagai, Hirotoshi Matsui, Akira Yamane, Masahiro Kawashima, Junko Suzuki, Hiroyuki Tashimo, Nobuharu Ohshima, Kimihiko Masuda, Atsuhisa Tamura, Shinobu Akagawa, Akira Hebisawa, Ken Ohta
Internal Medicine.2017; 56(19): 2661. CrossRef
Tuberculous Periportal Lymphadenitis: A Diagnostic Challenge
Jose Manuel Ramia, Miguel Diaz-Morfa, Alejandra Caminoa, Luis Gijón, Roberto de la Plaza
Cirugía Española (English Edition).2016; 94(3): 194. CrossRef
Linfadenitis periportal tuberculosa: un reto diagnóstico
Jose Manuel Ramia, Miguel Diaz-Morfa, Alejandra Caminoa, Luis Gijón, Roberto de la Plaza
Cirugía Española.2016; 94(3): 194. CrossRef
Obstructive Jaundice Caused by Tuberculous Lymphadenopathies
Ju Ri Kim, Ji Woong Jang, So Hee Chung, Min Kyu Kang, Jin Young Kim, Jun Hyung Park
Soonchunhyang Medical Science.2015; 21(2): 232. CrossRef